Multiple sclerosis (MS) is considered a prototypic autoimmune disease of the central nervous system (CNS). A complex genetic background with the HLA-DR15 haplotype as the main genetic risk factor and over 100 mostly immune-related minor risk alleles as well as several environmental factors ...
Our incomplete understanding of the causes and pathways involved in the onset and progression of multiple sclerosis (MS) limits our ability to effectively treat this complex neurological disease. Recent studies explore the role of immune cells at different stages of MS and how they interact with cel...
Multiple sclerosis (MS), a putative autoimmune disease of unknown etiology, is characterized by CNS perivascular inflammation, foci of demyelination, and elevated intrathecal production of oligoclonal IgG's. T and B cells, macrophages, and microglia are all implicated in contributing to the initiation...
Multiple sclerosis (MS) is a leading cause of chronic neurological disability in young to middle-aged adults, affecting ~2.5 million people worldwide. Currently, most therapeutics for MS are systemic immunosuppressive or immunomodulatory drugs, but these drugs are unable to halt or reverse the diseas...
The New Era of Multiple Sclerosis Therapeutics The early 1990s began a new era in the treatment of MS, when the FDA approved interferon beta-1b as the first treatment for reducing the rate of relapses. ... Bakshi,Rohit - 《Neurotherapeutics the Journal of the American Society for Experimenta...
Recent advances in the understanding of the immunology of multiple sclerosis (MS) are discussed. In the central nervous system (CNS) major histocompatibili... T Olsson - 《Current Opinion in Neurology & Neurosurgery》 被引量: 153发表: 1992年 The neuroimmunology of multiple sclerosis. The aim ...
metabolism and neurodegenerative signatures that were shared with autoimmune-driven neuroinflammation in multiple sclerosis mice. Our data provide an interactive resource for investigation of the immunology of blood proteins that could support therapeutic targeting of microglia activation by immune and vascular...
Herndon, R.M. (2003). Multiple sclerosis: Immunology, pathology, and pathophysiology. New York: Demos Medical Publishing, Inc.Herndon, R. M. (2003). Multiple sclerosis: Immunology, pathology and pathophysiology. In R. M. Herndon (Ed.), The pathology of multiple sclerosis and its variants (...
suggesting a possible mechanism for DMF in multiple sclerosis through NLRP3 inhibition. The derivatives also reduced pro-IL-1α cleavage in response to the calcium ionophore ionomycin. Together, these findings reveal the immunometabolic regulation of both the priming and activation steps of NLRP3 activ...
Multiple Sclerosis ImmunologyMultiple Sclerosis Immunologydemyelinating diseasemultiple sclerosismyelin basic proteinT cellsimmune responseautoimmunityA Foundation for Current and Future Treatmentsdoi:10.1007/978-1-4614-7953-6Yamamura, TakashiGran, BrunoSpringer...